Mesenchymal stem cell-mediated delivery boosts the efficacy of suicide gene therapy based on retroviral replicating vectors in peritoneally disseminated cancer

Our plain-English summary of Mesenchymal stem cell-mediated delivery boosts the efficacy of suicide gene therapy based on retroviral replicating vectors in peritoneally disseminated cancer, by S. Kubo, Y. Takeuchi, E. Sonoda-Fukuda, et al (Cancer Gene Therapy, 2026).

The study

• Authors: S. Kubo, Y. Takeuchi, E. Sonoda-Fukuda, N. Ogawa, S. Shinoda, A. Nakano-Doi, T. Nakagomi, S. Funaki, N. Kasahara
• Journal: Cancer Gene Therapy
• Published: 2026;33(8):909-918
• Read it: PubMed · Publisher · Free full text

Abstract

Retroviral replicating vectors (RRVs) hold promise for cancer gene therapy but face limitations due to their relatively low titers and susceptibility to inactivation by body fluids, limiting their application to intratumoral delivery. To overcome these challenges and target metastatic cancers, we investigated the use of tumor-homing mesenchymal stem cells (MSCs) as RRV carriers in a clinically relevant model of malignant peritoneal mesothelioma. MSCs derived from adipose tissue, bone marrow, and umbilical cord demonstrated significant migration toward mesothelioma cells and were permissive to RRV infection and production. MSCs transferred RRVs to tumor cells more effectively in direct co-culture than in Transwell assays. Using peritoneally disseminated cancer models, we confirmed that MSCs enhanced RRV transfer, even under ascites-mimicking conditions. In vivo biomolecular imaging and flow cytometry revealed markedly reduced RRV transduction under ascites conditions; however, MSC/RRV delivery significantly enhanced intratumoral viral transmission. Furthermore, while both direct RRV and MSC/RRV treatments were effective in non-ascites models, MSC/RRV delivery achieved superior antitumor efficacy in ascites-mimicking models, resulting in robust tumor suppression and prolonged survival. These findings highlight the potential of MSCs to overcome the limitations of RRV and suggest that MSC-based RRV-mediated suicide gene therapy represents a promising strategy for peritoneally disseminated cancers complicated by cancerous ascites.

© 2026. The Author(s).

In plain English

This laboratory and animal study tested whether human mesenchymal stem cells (MSCs) could carry retroviral replicating vectors (RRVs) to tumours in mouse models of peritoneally disseminated malignant mesothelioma, using the human mesothelioma line MSTO-211H. MSCs from adipose tissue, bone marrow and umbilical cord all migrated toward tumour cells (adipose-derived MSCs, MSC-ad, migrated most), could be infected by RRV and produced virus, though less than MSTO-211H cells. RRV passed from MSC-ad to tumour cells across a Transwell filter with an infection efficiency of 44.8 plus or minus 2.1 percent, and in direct co-culture 58.8 percent of cells were GFP- and mCherry-positive, an estimated overall infection efficiency of 94.1 percent. With the suicide gene (cytosine deaminase) and the prodrug 5-FC, an MSC ratio above 0.5 percent produced more than 90 percent tumour cell death at 10 mM 5-FC. In mice given human serum to mimic ascites, direct RRV injection transduced tumours poorly while MSC-delivered RRV remained efficient; in the ascites model all PBS mice died by day 56 and all RRV-CD mice by day 98, while MSC-ad/RRV-CD gave greater tumour suppression and longer survival. The authors concluded this is promising preclinical evidence.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Preclinical laboratory study: in vitro cell culture experiments plus mouse xenograft (animal) experiments
• Who was studied: Human cell lines (MSTO-211H mesothelioma, normal human mesothelial cells, 293T) and commercially purchased human MSCs from adipose tissue, bone marrow and umbilical cord; female BALB/c-nu/nu nude mice bearing intraperitoneal MSTO-211H/mCherry xenografts (n = 5 per group for imaging experiments; n = 10 per group for therapy experiments), Hyogo Medical University, Japan
• Exposure: Retroviral replicating vectors (RRV-GFP, RRV-fLuc/Venus, RRV-CD derived from amphotropic murine leukemia virus) delivered either directly or carried by MSCs, with the prodrug 5-fluorocytosine (5-FC) given at 500 mg/kg three times weekly in vivo; 10% pooled human serum used to mimic ascites
• Main results:
  • All three MSC types migrated significantly toward MSTO-211H cells, with adipose-derived MSCs showing the highest migratory capacity
  • All MSC subtypes could be infected by RRV, but less efficiently than MSTO-211H tumour cells; MSC-uc had the highest infectivity and MSC-ad the lowest
  • In a Transwell assay, RRV released from MSC-ad infected 44.8 ± 2.1% of MSTO-211H tumour cells in the lower chamber
  • In direct co-culture, GFP- and mCherry-positive tumour cells were 58.8% of the population, giving an estimated overall infection efficiency of 94.1%
  • In co-culture with MSC-ad/RRV-CD and 5-FC, an MSC proportion above 0.5% caused more than 90% tumour cell death at 10 mM 5-FC
  • In vivo without ascites, MSC-ad and MSC-uc achieved higher tumour transduction than MSC-bm or direct RRV administration
  • Under ascites-mimicking conditions, direct intraperitoneal RRV gave markedly reduced tumour transduction while MSC-delivered RRV remained efficient
  • In non-ascites treated mice, all PBS and MSC-ad mice died by day 75, while RRV-CD and MSC-ad/RRV-CD groups survived beyond day 75; one mouse in each group died on day 105 and day 130, the remaining nine in both groups surviving until day 174
  • In ascites-mimicking mice, all PBS mice died by day 56 and all RRV-CD mice by day 98, while MSC-ad/RRV-CD showed significantly greater tumour suppression and a survival benefit
• The authors' conclusion: The authors concluded that the study provides preclinical evidence that MSC-based RRV suicide gene therapy is a promising strategy for peritoneally disseminated cancers with ascites
• Limitations the authors state:
  • Treatment was started at the same time as ascites induction, which the authors describe as a prophylactic-like setting rather than treatment of fully established ascites
  • Human serum only partially reproduces malignant ascites, so further studies with authentic ascites samples are needed
  • MSCs vary by donor, tissue origin and culture conditions, so validation with multiple donors and tumour models is needed
  • The effect of MSCs on tumour growth may differ by tumour type and needs further evaluation

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma, Peritoneal mesothelioma.

Medical terms in this study, explained in our Lexicon: STEM, Peritoneal Mesothelioma, Mesothelioma, Ascites.

Related studies

• Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma — E.K. Sage, K.K. Kolluri, et al. (2014)
• Mesenchymal stem cells modulate lung injury — A.R. Brody, K.D. Salazar, et al. (2010)
• Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus — S. Kubo, M. Takagi-Kimura, et al. (2013)
• Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy — X.B. Deng, L. Xiao, et al. (2015)
• Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma — M.J. Lathrop, E.K. Sage, et al. (2015)
• Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation — S. Mukherjee, T. Haenel, et al. (2000)

Browse more research in Cancer Gene Therapy, or return to medical research.